Makers Laboratories Ltd
Makers Laboratories has a liquidity profile that is relatively strong, with a current ratio of 3.22, indicating the company can cover its short-term obligations more than three times over. However, the company reported negative operating cash flow of INR 40.79 million, which raises concerns about its ability to sustain operations without external financing. The company's debt-to-equity ratio is low at 0.07, suggesting minimal leverage and a conservative capital structure. In terms of profitability, Makers Laboratories has a return on equity (ROE) of 10.62% and a return on assets (ROA) of 5.06%, which are both positive but should be compared to industry medians to assess relative performance. The company's net income of INR 74.91 million is derived from a gross profit of INR 666.85 million, indicating a relatively healthy margin structure. The company's revenue is concentrated in the Indian market, with no disclosed international operations. Its segments include Pharmaceutical and Chemical Manufacturing, with no further breakdown of geographic or product line contributions provided in the data. This lack of diversification could pose a concentration risk if the Indian market experiences regulatory or economic shifts. Looking ahead, the company's revenue outlook is not explicitly provided, but the operating cash flow and free cash flow figures suggest a mixed financial trajectory. Free cash flow of INR 117.52 million indicates some capacity for reinvestment or shareholder returns, but the negative operating cash flow suggests ongoing operational challenges. The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no immediate pressure from share issuance or dilutive events. However, the negative operating cash flow could necessitate future financing, which may introduce dilution risk if not managed through internal cash generation. Recent filings and transcripts are not provided in the input data, so no specific events can be cited. However, the financial snapshot indicates a need for close monitoring of cash flow trends and capital structure decisions.
Business. Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations, primarily in the Indian market, with product lines including Duramol, Artemak-AB, and Exylin.
Classification. Makers Laboratories is classified under the Pharmaceuticals industry within the Healthcare economic sector, with a confidence level of 0.92 based on verified market data.
- Makers Laboratories has a strong current ratio but reports negative operating cash flow, indicating potential liquidity challenges.
- The company's ROE and ROA are positive but should be benchmarked against industry medians for a complete assessment.
- Revenue is concentrated in the Indian market, with no international diversification disclosed.
- Free cash flow is positive, suggesting some capacity for reinvestment or shareholder returns.
- The company's debt-to-equity ratio is low, indicating a conservative capital structure.
- The risk assessment highlights a medium liquidity risk and low dilution risk.
- --
- ## RATIONALES
- Net cash is negative after subtracting total debt.